Please use this identifier to cite or link to this item: https://accedacris.ulpgc.es/jspui/handle/10553/162931
Title: Fatigue in pediatric patients with inflammatory bowel disease: a multicenter study by the SEGHNP
Authors: Martin-Masot, Rafael
Rodríguez-Belvís, Marta
Palomino, Laura
Pujol Muncunill, Gemma
Sánchez Sánchez, César
Martín de Carpi, Javier
Navas-López, Víctor Manuel
Peña Quintana, Luis* 
UNESCO Clasification: 32 Ciencias médicas
3206 Ciencias de la nutrición
320110 Pediatría
Keywords: Children
Pediatric inflammatory bowel disease
Fatigue
Health-related quality of life
IMPACT-III questionnaire
Issue Date: 2025
Journal: Crohn''s and Colitis 360 
Abstract: Background: Fatigue is a common and disabling symptom in pediatric inflammatory bowel disease (IBD), often persisting even during clinical remission and reflecting a multifactorial origin. Despite its significant impact on patients' lives, it remains under-recognized. The IMPACT-III and IMPACT-III-P questionnaires facilitate fatigue assessment within a biopsychosocial framework of health-related quality of life (HRQOL). Methods: In this multicenter study supported by the Spanish Society of Pediatric Gastroenterology, Hepatology and Nutrition (SEGHNP), 382 patients aged 10-17 years and their caregivers from 37 hospitals completed the IMPACT-III and IMPACT-III-P questionnaires between February 2021 and June 2023. Fatigue-related items were analyzed, and predictive models were de veloped using univariate and multivariate logistic regression. Results: A total of 370 patient questionnaires were included in the analysis. The median age at diagnosis was 11.3 years (inter quartile range [IQR] 8.7-13.3), and at assessment, 14.4 years (IQR 12.4–16.1). Males represented 56% of the cohort, and 61.1% had Crohn’s disease. Treatments included immunosuppressants (44.6%), 5-ASA (33.7%), biologics (30.8%), corticosteroids (6%), and other therapies (27.8%). Fatigue was reported by 81.1% of patients, including 77.5% of those in clinical remission. Severe fatigue was significantly associated with female sex, older age, active disease, and dietary treatment. Conversely, absence of fatigue was independently associated with male sex, earlier pubertal stage, and not receiving biologics. Notable discrepancies were observed between patient and caregiver perceptions of energy levels. Fatigue correlated with significant ly lower HRQOL scores across all IMPACT-III domains. In Crohn’s disease, the strongest impacts were observed in the social and systemic domains, whereas in ulcerative colitis, emotional and physical domains were more affected. Patients without severe fatigue consistently scored higher in all domains. Conclusion: Fatigue is a highly prevalent and multifactorial symptom in pediatric IBD, with a marked negative impact on qual ity of life, even in clinical remission. The IMPACT-III and IMPACT-III-P questionnaires are valuable tools for its assessment and highlight the need for routine, systematic evaluation of fatigue to guide holistic and individualized management strategies.
URI: https://accedacris.ulpgc.es/jspui/handle/10553/162931
ISSN: 2631-827X
DOI: 10.1093/crocol/otag005
Source: Crohn''s and Colitis 360 [eISSN 2631-827X], v. 8(1) (febrero 2026)
Appears in Collections:Artículos
Adobe PDF (1,51 MB)
Show full item record

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.